Skip to content
AwardedFinlandGoods

Tisagenlekleuseelivalmiste (Kymriah) lapsipotilaille tai korkeintaan 25 vuoden ikäisille nuorille aikuispotilaille

Published
Published 8 December 2025

Overview

Tisagenlekleuseelivalmiste (Kymriah 1.2x10e6-6x10e8 solua infuusioneste) Terveydenhuollon palveluvalikoimaneuvoston (Palko) suosituksen (13.3.2019) mukaiseen käyttöön lapsipotilaiden ja korkeintaan 25 vuoden ikäisten nuorten aikuispotilaiden B-solulinjan akuutin lymfoblastisen leukemian (ALL) hoidossa, kun sairaus ei ole reagoinut aiempaan hoitoon (hoitoresistentti), kun se on uusiutunut kaksi kertaa tai useammin tai kun se on uusiutunut kantasolusiirron jälkeen.

Key details

Country
Finland
Status
Awarded
Category
Goods
Procedure
Direct
Published
8 December 2025
Classification (CPV)
Pharmaceutical products

Award outcome

Awarded value
€2,000,000
Award date
28 December 2025
Contract period
1 January 2026 → 31 December 2027
Winner
  • Novartis Finland Oy

Contract ending soon? Skim tracks incumbents and flags recompetes early. Book a demo to set up alerts.

Notice history

Every published notice in this contracting process, newest first.

  1. Contract Award Notice

    28 January 2026

  2. Contract Notice

    8 December 2025

Contracting authority

  • HUS Group, the joint authority for Helsinki and Uusimaa

    Procuring entity

    Helsinki, Finland

    Authority website ↗

Get the full picture

AI analysis, bid scoring, and expert strategy for this tender

Skim analyses every tender against your company profile and tells you whether to bid, how to win, and who you are up against.

See which competitors are winning the contracts you're chasing.

15-minute call. We'll pull the win data on your real pipeline and show you what Skim does with it.

Awarded: Tisagenlekleuseelivalmiste (Kymriah) lapsipotilaille tai korkeintaan 25 vuoden ikäisille nuorille aikuispotilaille — won by Novartis Finland Oy — Skim